The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2021
DOI: 10.1007/s11657-021-00925-6
|View full text |Cite
|
Sign up to set email alerts
|

Fracture liaison service model: treatment persistence 5 years later

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
9
3
2

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 14 publications
(15 citation statements)
references
References 18 publications
1
9
3
2
Order By: Relevance
“…Most patients who start treatment will remain in treatment up to 5 years, according to retrospective administrative data collected on 888 patients. 24 In our study, the probability of adherence to 3 months of treatment with bisphosphonates or denosumab was 93.5% and 97.3% in groups A and B, respectively, which was not significantly different (p = 0.273); the 1-year adherence rates were 51.9% and 73.5%, and the 3-year adherence rates were 26% and 57.5%, respectively. Thus, in comparison with those who did not receive OWFLS, adherence was better in patients included in OWFLS (p = 0.003, p < 0.0001, respectively).…”
Section: Discussioncontrasting
confidence: 46%
“…Most patients who start treatment will remain in treatment up to 5 years, according to retrospective administrative data collected on 888 patients. 24 In our study, the probability of adherence to 3 months of treatment with bisphosphonates or denosumab was 93.5% and 97.3% in groups A and B, respectively, which was not significantly different (p = 0.273); the 1-year adherence rates were 51.9% and 73.5%, and the 3-year adherence rates were 26% and 57.5%, respectively. Thus, in comparison with those who did not receive OWFLS, adherence was better in patients included in OWFLS (p = 0.003, p < 0.0001, respectively).…”
Section: Discussioncontrasting
confidence: 46%
“…These sensitivity analyses showed that the introduction of more conservative FLS also would provide favorable efficiency results from the SNS perspective. As recent data on the evolution of persistence in FLS become available at Spanish level, 50 a sensitivity scenario analysis was conducted supporting the results of the base case. Although the results of this scenario should be treated with caution due to differences in patient characteristics between studies, it also suggested that implementing an FLS program would provide clinical benefits to patients (0.003 LY and 0.035 QALY per patient) with limited incremental costs of € 356,32 per patient, resulting in an ICUR below the commonly accepted willingness-to-pay thresholds.…”
Section: Discussionmentioning
confidence: 92%
“…15,28 Another cross-sectional study found that one-third of NH residents with the diagnosis of osteoporosis receive treatment. 29 FLS have been shown to achieve high rates of osteoporosis treatment and adherence in community-dwellers, 30,31 Additional investigation is needed to determine whether this model improves the quality of shared decision-making and osteoporosis treatment rates in the NH setting.…”
Section: Discussionmentioning
confidence: 99%